Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRABECTEDIN vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Unresectable or metastatic liposarcoma or leiomyosarcoma after prior anthracycline-containing therapy,Metastatic soft tissue sarcoma (EU)
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
1.5 mg/m² intravenously over 24 hours every 3 weeks.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life ranges from 26 to 40 hours (mean ~33 hours) in patients with normal hepatic function, allowing for a 3-weekly dosing interval.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP3A4; also a substrate of P-glycoprotein.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily fecal (approximately 58% of administered dose) with minor renal excretion (about 21% as unchanged drug and metabolites). Biliary excretion accounts for a significant portion of elimination via feces.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 97-98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 85-90% bound to serum albumin.
Volume of distribution at steady state is approximately 1000 L (>10 L/kg), indicating extensive tissue distribution and binding.
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Not applicable; administered intravenously. Oral bioavailability is negligible due to extensive first-pass metabolism.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Contraindicated in patients with severe hepatic impairment (Child-Pugh C). For moderate hepatic impairment (Child-Pugh B), reduce starting dose to 0.9 mg/m². For mild hepatic impairment (Child-Pugh A), no dose adjustment but monitor closely.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Safety and efficacy not established in pediatric patients.
Not established; safety and efficacy not determined in pediatric patients.
No specific dose adjustment recommended based on age alone; monitor renal and hepatic function due to potential age-related decline.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Trabectedin is associated with severe and fatal neutropenic sepsis, rhabdomyolysis with renal failure, cardiotoxicity (cardiomyopathy, heart failure), hepatotoxicity, and extravasation leading to tissue necrosis. It should only be administered under the supervision of a qualified healthcare provider experienced in the use of antineoplastic agents.
None.
Myelosuppression (neutropenia, thrombocytopenia, anemia), hepatotoxicity (elevated liver enzymes, bilirubin, hepatic failure), cardiotoxicity (LVEF decline, heart failure), rhabdomyolysis, extravasation injury, hypersensitivity reactions, and embryo-fetal toxicity.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to trabectedin or any of its excipients, concomitant use with yellow fever vaccine, severe hepatic impairment.
Hypersensitivity to AURLUMYN or any of its components.
Grapefruit and grapefruit juice should be avoided as they may increase trabectedin levels. There are no other specific dietary restrictions.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Trabectedin is teratogenic based on animal studies. It is contraindicated in pregnancy. First trimester exposure carries high risk of major malformations and pregnancy loss. Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Effective contraception is required during treatment and for at least 3 months after the last dose.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Unknown if trabectedin is excreted in human milk; however, due to potential serious adverse reactions in breastfeeding infants, women should discontinue breastfeeding during treatment and for at least 3 weeks after the last dose. M/P ratio is not available.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No clinical data are available for dose adjustments during pregnancy. Trabec... is contraindicated in pregnancy; therefore, no dose adjustment is recommended. If inadvertent exposure occurs, immediate discontinuation and supportive care are advised.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Trabectedin is a marine-derived alkylating agent indicated for advanced soft tissue sarcoma (STS) and relapsed platinum-sensitive ovarian cancer. It requires dexamethasone premedication to reduce hepatotoxicity. Monitor liver function tests (LFTs) closely; dose reduction or interruption is needed for transaminase elevation. Administer via central line due to vesicant properties. Consider cardiac monitoring as QT prolongation can occur. Use with caution in patients with hepatic impairment.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
This medication is given intravenously over 24 hours through a central line.,You will receive dexamethasone before each infusion to help prevent liver side effects.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe fatigue.,Avoid grapefruit and grapefruit juice during treatment.,Use effective contraception during treatment and for at least 3 months after the last dose.,Do not breastfeed during treatment and for 3 months after the last dose.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
"Trabectedin, a potent anticancer agent, inhibits the cytochrome P450 (CYP) enzyme CYP3A4, which is primarily responsible for the metabolism of cyclosporine. When co-administered, trabectedin decreases the clearance of cyclosporine, leading to significantly elevated cyclosporine blood concentrations. This increased exposure raises the risk of cyclosporine-related toxicities, particularly nephrotoxicity, hepatotoxicity, and immunosuppression-related complications, potentially requiring dose adjustments and close monitoring."
"Nilotinib is primarily metabolized by CYP3A4, and trabectedin is a moderate inhibitor of CYP3A4. Concomitant use may increase nilotinib exposure, leading to elevated plasma concentrations and a higher risk of QT prolongation, torsade de pointes, and sudden cardiac death. This interaction requires cautious monitoring and potential dose adjustment."
"Trabectedin, an alkylating agent used for soft tissue sarcoma, is metabolized primarily by CYP3A4. Posaconazole, a potent CYP3A4 inhibitor, can significantly increase trabectedin exposure by reducing its clearance. This elevated concentration may enhance trabectedin-induced hepatotoxicity and myelosuppression, increasing the risk of severe adverse effects such as elevated liver enzymes and febrile neutropenia."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRABECTEDIN vs AURLUMYN, answered by our medical review team.
TRABECTEDIN is a Antineoplastic Agent that works by Trabectedin binds to the minor groove of DNA, forming adducts that lead to DNA strand breaks and inhibition of transcription. It also affects the tumor microenvironment by modulating cytokine production and inhibiting activated macrophages.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRABECTEDIN and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRABECTEDIN is: 1.5 mg/m² intravenously over 24 hours every 3 weeks.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRABECTEDIN and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRABECTEDIN is classified as Category C. Trabectedin is teratogenic based on animal studies. It is contraindicated in pregnancy. First trimester exposure carries high risk of major malformations and pregnancy loss. Second. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.